MESOMICS: molecular characterization of malignant pleural mesothelioma

Lynnette Fernandez-Cuesta, PhD, International Agency for Research on Cancer (IARC-WHO), Lyon, France, provides an overview of the MESOMICS project, which aims to provide an multi-omics analysis of malignant pleural mesothelioma (MPM), which currently has poor outcomes. MPM is primarily caused by exposure to asbestos, and cases are increasing. By understanding the biology of the disease, novel targets and therapies can be elucidated and developed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.